Pharmacokinetics of chloroquine in patients with malaria by P. vivax from the Western Brazilian Amazon basin

Biomed Pharmacother. 2022 May:149:112874. doi: 10.1016/j.biopha.2022.112874. Epub 2022 Apr 5.

Abstract

The western Amazon basin is an important endemic area for malaria by P. vivax. In recent years, several reports showed the treatment failure with chloroquine, which can be related to resistance. The assessment of chloroquine resistance requires the evaluation of drug exposure, and when possible, the estimation of the pharmacokinetic parameters. However, there is no data on the pharmacokinetics of chloroquine in this endemic area. Moreover, the influence of the early reappearance of parasites in blood on the exposure to the drug was low exploited in the literature. The present study described the pharmacokinetic parameters of chloroquine in whole blood of adult patients with P. vivax malaria from the western Brazilian Amazon basin and compared the area under the curve (AUC) with the parasitological outcome at day 28. A total of 19 patients with parasite recurrence within 28 days and 20 patients with no recurrence were included in the study. Chloroquine was measured by high-performance liquid chromatography (HPLC). The pharmacokinetic parameters were estimated by non-compartmental modeling. The maximum concentration ranged from 1285 to 2030 ng/mL. The terminal half-life varied from 5.3 to 12.8 days. The volume of distribution from 1090 to 2340 L/kg, and the area under the curve to the last measurable concentration from 247 to 432 ng/mL.h. The pharmacokinetic parameters were similar in both groups, which suggests the lack of influence of early reappearance of parasites on chloroquine pharmacokinetics.

Keywords: Chloroquine; Malaria; Pharmacokinetics; Plasmodium vivax; Therapeutic failure.

MeSH terms

  • Adult
  • Antimalarials* / pharmacology
  • Brazil
  • Chloroquine / pharmacokinetics
  • Chloroquine / therapeutic use
  • Drug Resistance
  • Humans
  • Malaria, Vivax* / chemically induced
  • Malaria, Vivax* / drug therapy
  • Malaria, Vivax* / parasitology
  • Plasmodium vivax
  • Treatment Failure

Substances

  • Antimalarials
  • Chloroquine